Fibroblast Growth Factor Receptor Family Members as Prognostic Biomarkers in Head and Neck Squamous Cell Carcinoma: A Systematic Review

BackgroundSince head and neck cancer is characterized by poor survival rates, there is a demand for novel therapeutic targets and prognostic biomarkers. An upcoming therapeutic target is the fibroblast growth factor receptor (FGFR) family. However, their prognostic role in head and neck cancer remains unclear.ObjectiveTo systematically review current evidence on the prognostic value of FGFR family members in head and neck squamous cell carcinoma (HNSCC).MethodsA systematic search of PubMed, Embase, and the Cochrane Library was performed for publications up to 14 May 2014. Two reviewers screened all articles and included prognostic studies on the molecular biomarkers FGFR1-5 in any type of HNSCC. Relevant studies were assessed on risk of bias using the Quality in Prognostic Studies (QUIPS) tool. Data on FGFR aberrations and survival outcome were extracted from relevant studies. The prognostic value of FGFR aberrations was compared among studies.ResultsThe initial search yielded 1568 publications of which 12 fulfilled the inclusion criteria. Four studies reported FGFR1 gene amplification (9.3–17.4 %) and FGFR1 protein overexpression (11.8 %) in HNSCC. FGFR1 protein expression by cancer-associated fibroblasts correlated with poor survival outcome in one study (p < 0.01). Eight studies reported high rates of FGFR4 Gly388Arg polymorphisms (32.5–54.2 %) and FGFR4 protein overexpression (16–35 %), with varying correlations with survival. So far, no studies assessed the prognostic role of FGFR2, FGFR3, or FGFR5 in HNSCC.LimitationsSignificant risk of bias has been identified among included studies. Therefore, cautious interpretation of the results is recommended.ConclusionIn conclusion, evidence was found for prognostic value of FGFR1 expression in cancer-associated fibroblasts in HNSCC. Prognostic evidence on the other FGFR family members in HNSCC is limited and conflicting. This emphasizes the need for future well-conducted prognostic studies.

• Publication year

  2015

• Venue

  Targeted oncology

• Publication date

  2015-06-27

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11523-015-0374-9PMID 26115874PMCID 4759209
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Therapeutic insights from genomic studies of head and neck squamous cell carcinomas.

  2015cited by this paper
• Comprehensive genomic characterization of head and neck squamous cell carcinomas

  2015cited by this paper
• Nodal metastasis and survival in oral cancer: Association with protein expression of SLPI, not with LCN2, TACSTD2, or THBS2

  2015cited by this paper
• Integrative and Comparative Genomic Analysis of HPV-Positive and HPV-Negative Head and Neck Squamous Cell Carcinomas

  2014cited by this paper
• FGFR3 expression in primary and metastatic urothelial carcinoma of the bladder

  2014cited by this paper
• Prognostic role of FGFR1 amplification in early-stage non-small cell lung cancer

  2014cited by this paper
• Genomic aberrations in the FGFR pathway: opportunities for targeted therapies in solid tumors.

  2014influential reference
• Fibroblast growth factor receptor 4 (FGFR4): a targetable regulator of drug resistance in colorectal cancer

  2014cited by this paper
• Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer: a systematic review and meta-analysis.

  2014cited by this paper
• FGFR1 amplification is associated with poor prognosis and smoking in non-small-cell lung cancer

  2014cited by this paper
• Emergence of FGFR family gene fusions as therapeutic targets in a wide spectrum of solid tumours

  2014cited by this paper
• Prevalence, morphology, and natural history of FGFR1-amplified lung cancer, including squamous cell carcinoma, detected by FISH and SISH

  2014cited by this paper
• Differences in methylation profiles between HPV-positive and HPV-negative oropharynx squamous cell carcinoma

  2014cited by this paper
• Fibroblast growth factor receptor 1 amplification is a common event in squamous cell carcinoma of the head and neck

  2013cited by this paper
• Frequency of fibroblast growth factor receptor 1 gene amplification in oral tongue squamous cell carcinomas and associations with clinical features and patient outcome.

  2013influential reference
• Assessing Bias in Studies of Prognostic Factors

  2013cited by this paper
• Targeting FGFR with Dovitinib (TKI258): Preclinical and Clinical Data in Breast Cancer

  2013cited by this paper
• Prognostic Value of Fibroblast Growth Factor Receptor 1 Gene Locus Amplification in Resected Lung Squamous Cell Carcinoma

  2013cited by this paper
• Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives.

  2013cited by this paper
• Fibroblast growth factor receptor 1 gene amplification is associated with poor survival and cigarette smoking dosage in patients with resected squamous cell lung cancer.

  2013cited by this paper
• Strong expression of survivin is associated with positive response to radiotherapy and improved overall survival in head and neck squamous cell carcinoma patients

  2013cited by this paper
• The molecular pathogenesis of head and neck squamous cell carcinoma.

  2012cited by this paper
• FGFR4 Profile as a Prognostic Marker in Squamous Cell Carcinoma of the Mouth and Oropharynx

  2012influential reference
• Mutational Status of FGFR3 in Oral Squamous Cell Carcinoma

  2012cited by this paper
• FGFR1 Amplification in Squamous Cell Carcinoma of The Lung

  2012cited by this paper
• ECRG1 and FGFR4 single nucleotide polymorphism as predictive factors for nodal metastasis in oral squamous cell carcinoma

  2012influential reference
• Evaluation of tyrosine receptor kinases in the interactions of head and neck squamous cell carcinoma cells and fibroblasts.

  2012cited by this paper
• FGF Receptor Inhibitors: Role in Cancer Therapy

  2012cited by this paper
• Hallmarks of cancer: the next generation.

  2011cited by this paper
• Targeting fibroblast growth factor receptor 3 enhances radiosensitivity in human squamous cancer cells

  2011cited by this paper
• The molecular biology of head and neck cancer

  2011cited by this paper
• Validation of Genetic Sequence Variants as Prognostic Factors in Early-Stage Head and Neck Squamous Cell Cancer Survival

  2011influential reference
• Roles of Fibroblast Growth Factor Receptors in Carcinogenesis

  2010cited by this paper
• Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis.

  2010cited by this paper
• FGFR4 polymorphism, TP53 mutation, and their combinations are prognostic factors for oral squamous cell carcinoma.

  2010influential reference
• Overexpression of KLF13 and FGFR3 in Oral Cancer Cells

  2010cited by this paper
• Polymorphism of FGFR4 in cancer development and sensitivity to cisplatin and radiation in head and neck cancer.

  2009cited by this paper
• Resistance to Chemotherapy Is Associated with Fibroblast Growth Factor Receptor 4 Up-Regulation

  2009cited by this paper
• The FGF family: biology, pathophysiology and therapy

  2009cited by this paper
• Head and neck cancer

  2008cited by this paper
• The fibroblast growth factor receptor 4 (FGFR4) Arg388 allele correlates with survival in head and neck squamous cell carcinoma.

  2007influential reference
• Recurrent FGFR1 amplification and high FGFR1 protein expression in oral squamous cell carcinoma (OSCC).

  2007cited by this paper
• Evaluation of the Quality of Prognosis Studies in Systematic Reviews

  2006cited by this paper
• [Expression of basic fibroblast growth factor and its double receptors in laryngeal squamous cell carcinoma and its significance].

  2006cited by this paper
• FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.

  2006cited by this paper
• Correlation of basic fibroblast growth factor expression with the invasion and the prognosis of oral squamous cell carcinoma.

  2006cited by this paper
• FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancer.

  2006cited by this paper
• Treatment of advanced head and neck cancer: what lessons have we learned?

  2006cited by this paper
• Constitutive activating mutation of the FGFR3b in oral squamous cell carcinomas

  2005cited by this paper
• FGFR4 Gly388Arg polymorphism and prognosis of breast and colorectal cancer.

  2005cited by this paper
• G388R mutation of the FGFR4 gene is not relevant to breast cancer prognosis

  2004cited by this paper
• Involvement of the FGFR4 Arg388 allele in head and neck squamous cell carcinoma

  2004cited by this paper
• Molecular pathogenesis of head and neck squamous cell carcinoma

  2003cited by this paper
• Cancer progression and tumor cell motility are associated with the FGFR4 Arg(388) allele.

  2002cited by this paper
• Immunohistochemical localization of growth factors fibroblast growth factor-1 and fibroblast growth factor-2 and receptors fibroblast growth factor receptor-2 and fibroblast growth factor receptor-3 in normal oral epithelium, epithelial dysplasias, and squamous cell carcinoma.

  2002cited by this paper
• Fibroblast growth factors, their receptors and signaling.

  2000cited by this paper
• Expression of basic fibroblast growth factor and its receptors by head and neck squamous carcinoma tumor and vascular endothelial cells.

  1997cited by this paper
• Differential Expression of the Fibroblast Growth Factor Receptor (FGFR) Multigene Family in Normal Human Adult Tissues

  1997cited by this paper
• Molecular biology of head and neck cancer.

  1994cited by this paper
• Head and neck cancer.

  1991cited by this paper

• Genetic and Molecular Differences in Head and Neck Cancer Based on Smoking History.

  2025cites this paper
• Next-generation immunotherapies for head and neck squamous cell carcinoma: targeting novel immune checkpoints

  2025cites this paper
• Hydrogels as advanced drug delivery platforms for cancer immunotherapy: promising innovations and future outlook

  2025cites this paper
• Pharmacological and Biological Targeting of FGFR1 in Cancer

  2024cites this paper
• Characterization of Fibroblast Growth Factor Receptor Alterations and Activation in Patients with High-Risk Non-Muscle Invasive Bladder Cancer.

  2024cites this paper
• Deciphering ligand-receptor-mediated intercellular communication based on ensemble deep learning and the joint scoring strategy from single-cell transcriptomic data

  2023cites this paper
• New insights into RAS in head and neck cancer.

  2023cites this paper
• Prognostic Value and Clinical Significance of FGFR Genomic Alterations (GAs) in Metastatic Urothelial Cancer Patients

  2022cites this paper
• Hallmarks of Cancer Applied to Oral and Oropharyngeal Carcinogenesis: A Scoping Review of the Evidence Gaps Found in Published Systematic Reviews

  2022cites this paper
• Investigation of an FGFR-Signaling-Related Prognostic Model and Immune Landscape in Head and Neck Squamous Cell Carcinoma

  2022cites this paper
• Inhibition of FGF‐FGFR and VEGF‐VEGFR signalling in cancer treatment

  2021cites this paper
• FGFR4 Gly388Arg Polymorphism Reveals a Poor Prognosis, Especially in Asian Cancer Patients: A Meta-Analysis

  2021cites this paper
• Prognostic value of FGFR1 expression and amplification in patients with HNSCC: A systematic review and meta-analysis

  2021cites this paper
• Co-expression of fibroblast growth factor receptor 3 with mutant p53, and its association with worse outcome in oropharyngeal squamous cell carcinoma

  2021cites this paper
• Prognostic implications of Fibroblast growth factor receptor 1 (FGFR1) gene amplification and protein overexpression in hypopharyngeal and laryngeal squamous cell carcinoma

  2020cites this paper
• Fibroblast growth factor receptor 4 single nucleotide polymorphism Gly388Arg in head and neck carcinomas

  2019cites this paper
• Expression of FGF‐2/FGFR‐1 in normal mucosa, salivary gland, preneoplastic, and neoplastic lesions of the oral cavity

  2018cites this paper
• Cancer-associated fibroblasts in tumor microenvironment - Accomplices in tumor malignancy.

  2018cites this paper
• Prognostic importance of FGF2 and FGFR1 expression for patients affected by ameloblastoma

  2018cites this paper
• Fibroblast growth factor receptor 1 amplification in laryngeal squamous cell carcinoma

  2018cites this paper
• FGFR1 gene amplification in squamous cell carcinomas of the lung: a potential favorable prognostic marker for women and for patients with advanced cancer

  2018cites this paper
• Fibroblast growth factor receptor 1 and 3 expression is associated with regulatory PI3K/AKT kinase activity, as well as invasion and prognosis, in human laryngeal cancer

  2018cites this paper
• Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro.

  2017cites this paper
• FGFR1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma

  2016cites this paper
• FGFR 1 Is a Potential Prognostic Biomarker and Therapeutic Target in Head and Neck Squamous Cell Carcinoma

  2016cites this paper
• Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor

  2016cites this paper
• Evaluation of FGFR3 as a Therapeutic Target in Head and Neck Squamous Cell Carcinoma

  2016cites this paper
• FGFR Family Members Protein Expression as Prognostic Markers in Oral Cavity and Oropharyngeal Squamous Cell Carcinoma

  2016cites this paper
• FGFR4 Is a Potential Predictive Biomarker in Oral and Oropharyngeal Squamous Cell Carcinoma

  2015cites this paper
• Fibroblast growth factor receptor 3 protein is overexpressed in oral and oropharyngeal squamous cell carcinoma

  2015cites this paper